Your browser doesn't support javascript.
loading
Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes.
Rosak, C; Standl, E; Reblin, T; Stammer, H; Seidel, D K.
Affiliation
  • Rosak C; Krankenhaus Sachsenhausen, Department of Diabetology and Metabolic Disorders, Frankfurt, Germany.
Int J Clin Pract ; 60(9): 1040-7, 2006 Sep.
Article in En | MEDLINE | ID: mdl-16939544
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Thiazolidinediones / Diabetes Mellitus, Type 2 / Hypoglycemic Agents Type of study: Clinical_trials / Observational_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Int J Clin Pract Journal subject: MEDICINA Year: 2006 Document type: Article Affiliation country: Alemania Country of publication: India
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Thiazolidinediones / Diabetes Mellitus, Type 2 / Hypoglycemic Agents Type of study: Clinical_trials / Observational_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Int J Clin Pract Journal subject: MEDICINA Year: 2006 Document type: Article Affiliation country: Alemania Country of publication: India